Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21: 2787–2799. 10.1200/JCO.2003.01.504
Yoshida T, Zhang G, Haura EB: Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. Biochem Pharmacol 2010, 80: 613–623. 10.1016/j.bcp.2010.05.014
Ono M, Kuwano M: Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006, 12: 7242–7251. 10.1158/1078-0432.CCR-06-0646
Cohen S: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962, 237: 1555–1562.
Ausborn NL, Le QT, Bradley JD, et al.: Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2012, 83: e453-e464. 10.1016/j.ijrobp.2012.01.056
Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19: 6550–6565. 10.1038/sj.onc.1204082
Harari PM, Huang SM: Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 2004, 58: 976–983. 10.1016/j.ijrobp.2003.09.097
Milas L, Fan Z, Andratschke NH, Ang KK: Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004, 58: 966–971. 10.1016/j.ijrobp.2003.08.035
Raben D, Helfrich B, Bunn PA: Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 2004, 59: S27–38. 10.1016/j.ijrobp.2004.01.054
Cappuzzo F, Hirsch FR, Rossi E, et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005, 97: 643–655. 10.1093/jnci/dji112
Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al.: Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21: 3798–3807. 10.1200/JCO.2003.11.069
Herbst RS, Bunn PA: Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003, 9: 5813–5824.
Raben D, Helfrich B, Chan DC, et al.: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005, 11: 795–805.
Cascone T, Morelli MP, Ciardiello F: Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol 2006, Suppl 2: ii46-ii48.
Giaccone G, Herbst RS, Manegold C, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22: 777–784. 10.1200/JCO.2004.08.001
Herbst RS, Giaccone G, Schiller JH, et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22: 785–794. 10.1200/JCO.2004.07.215
Herbst RS, Prager D, Hermann R, et al.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23: 5892–5899. 10.1200/JCO.2005.02.840
Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361: 947–957. 10.1056/NEJMoa0810699
Mitsudomi T, Morita S, Yatabe Y, et al.: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG 3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11: 121–128. 10.1016/S1470-2045(09)70364-X
Zhou C, Wu Y, Chen G, et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12: 735–742. 10.1016/S1470-2045(11)70184-X
Inoue A, Kobayash K, Maemondo M, et al.: Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2012. In press.
Rosell R, Carcereny E, Gervais R, et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13: 239–246. 10.1016/S1470-2045(11)70393-X
Gridelli C, Ciardiello F, Gallo C, et al.: First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012, 30: 3002–3011. 10.1200/JCO.2011.41.2056
Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med 2004, 350: 2129–2139. 10.1056/NEJMoa040938
Yun CH, Boggon TJ, Li Y, et al.: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11: 217–227. 10.1016/j.ccr.2006.12.017
Kobayashi S, Boggon TJ, Dayaram T, et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352: 786–792. 10.1056/NEJMoa044238
Pao W, Miller VA, Politi KA, et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2: e73. 10.1371/journal.pmed.0020073
Kim ES, Hirsh V, Mok T, et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet Oncol 2008, 372: 1809–1818.
Ciuleanu T, Stelmakh L, Cicenas S, et al.: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomized multicentre, open-label, phase 3 study. Lancet Oncol 2012, 13: 300–308. 10.1016/S1470-2045(11)70385-0
Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11: 521–529. 10.1016/S1470-2045(10)70112-1
Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33: 369–385. 10.1053/j.seminoncol.2006.04.003
Rosell R, Robinet G, Szczesna A, et al.: Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19: 362–369. 10.1093/annonc/mdm474
Pirker R, Pereira J, Szczesna A, et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet Oncol 2009, 373: 1525–1531.
Lynch TJ, Patel T, Dreisbach L, et al.: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28: 911–917. 10.1200/JCO.2009.21.9618
Douillard JY, Shepherd FA, Hirsh V, et al.: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28: 744–752. 10.1200/JCO.2009.24.3030
Brugger W, Triller N, Blasinska-Morawiec M, et al.: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011, 29: 4113–4120. 10.1200/JCO.2010.31.8162
Milella M, Nuzzo C, Bria E, et al.: EGFR molecular profiling in advanced NSCLC a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol 2012, 7: 672–680. 10.1097/JTO.0b013e31824a8bde
Cadranel J, Mauguen A, Faller M, et al.: Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC Project-Part 2). J Thorac Oncol 2012, 7: 1490–1502. 10.1097/JTO.0b013e318265b2b5
Bai H, Mao L, Wang HS, et al.: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27: 2653–2659. 10.1200/JCO.2008.17.3930
Bell DW, Lynch TJ, Haserlat SM, et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23: 8081–8092. 10.1200/JCO.2005.02.7078
Eberhard DA, Johnson BE, Amler LC, et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23: 5900–5909. 10.1200/JCO.2005.02.857
Fukuoka M, Wu YL, Thongprasert S, et al.: Biomarker analysis and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29: 2866–2874. 10.1200/JCO.2010.33.4235
Hirsch FR, Herbst RS, Olsen C, et al.: Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26: 3351–3357. 10.1200/JCO.2007.14.0111
Khambata-Ford S, Harbison CT, Hart LL, et al.: Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28: 918–927. 10.1200/JCO.2009.25.2890
O’Byrne KJ, Gatzemeier U, Bondarenko I, et al.: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, 12: 795–805. 10.1016/S1470-2045(11)70189-9
Begg AC, Stewart FA, Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011, 11: 239–253. 10.1038/nrc3007
Riesterer O, Milas L, Ang KK: Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 2007, 25: 4075–4083. 10.1200/JCO.2007.11.8497
Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11: 21–28. 10.1016/S1470-2045(09)70311-0
Aupérin A, Le Péchoux C, Rolland E, et al.: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28: 2181–2190. 10.1200/JCO.2009.26.2543
Bianco C, Tortora G, Bianco R, et al.: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002, 8: 3250–3258.
Park SY, Kim YM, Pyo H: Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer 2010, 9: 222. 10.1186/1476-4598-9-222
Tanaka T, Munshi A, Brooks C, et al.: Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008, 14: 1266–1273. 10.1158/1078-0432.CCR-07-1606
Wang M, Morsbach F, Sander D, et al.: EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 2011, 71: 6261–6269. 10.1158/0008-5472.CAN-11-0213
Akashi Y, Okamoto I, Iwasa T, et al.: Enhancement of the antitumor activity of ionizing radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008, 98: 749–755. 10.1038/sj.bjc.6604222
Okamoto I, Takahashi T, Okamoto H, et al.: Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 2011, 72: 199–204. 10.1016/j.lungcan.2010.08.016
Choong NW, Mauer AM, Haraf DJ, et al.: Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008, 3: 1003–1011. 10.1097/JTO.0b013e31818396a4
Rothschild S, Bucher SE, Bernier J, et al.: Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. Int J Radiat Oncol Biol Phys 2011, 80: 126–132. 10.1016/j.ijrobp.2010.01.048
Wang J, Xia TY, Wang YJ, et al.: Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 81: e59-e65. 10.1016/j.ijrobp.2010.12.035
Center B, Petty WJ, Ayala D, et al.: A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 2010, 5: 69–74. 10.1097/JTO.0b013e3181c59a0e
Stinchcombe TE, Morris DE, Lee CB, et al.: Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008, 3: 250–257. 10.1097/JTO.0b013e3181653cf4
Ready N, Jänne PA, Bogart J, et al.: Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis Cancer and Leukemia Group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010, 5: 1382–1390. 10.1097/JTO.0b013e3181eba657
Chang CC, Chi KH, Kao SJ, et al.: Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mon-institutional experience. Lung Cancer 2011, 73: 189–194. 10.1016/j.lungcan.2010.12.007
Komaki RU, Kim YB, Wistuba II, et al.: Vimentin (EMT marker protein) score predicts resistance to erlotinib and radiotherapy for patients with stage III non-small cell lung cancer on a prospective phase II trial. J Thorac Oncol 2012, 7: S220.
Curran WJ Jr, Paulus R, Langer C: Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG9410. JNCI 2011, 22: 2499.
Hanna N, Neubauer M, Yiannoutsos C, et al.: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26: 5755–5760. 10.1200/JCO.2008.17.7840
Hughes S, Liong J, Miah A, et al.: A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRTACH study. J Thorac Oncol 2008, 3: 648–651. 10.1097/JTO.0b013e3181757a60
Choi HJ, Sohn JH, Lee CG, et al.: A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 2011, 71: 55–59. 10.1016/j.lungcan.2010.04.010
Bebb G, Smith C, Rorke S, et al.: Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIB, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011, 67: 837–845. 10.1007/s00280-010-1379-9
Govindan R, Bogart J, Stinchcombe T, et al.: Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407. J Clin Oncol 2011, 29: 3120–3125. 10.1200/JCO.2010.33.4979
Jensen AD, Münter MW, Bischoff HG, et al.: Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 2011, 117: 2988–2994.
Hallqvist A, Wagenius G, Rylander H, et al.: Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study Group. Lung Cancer 2011, 71: 166–172. 10.1016/j.lungcan.2010.05.011
Blumenschein GR Jr, Paulus R, Curran WJ, et al.: Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011, 29: 2312–2318. 10.1200/JCO.2010.31.7875
Hammerman PS, Pänne PA, Johnson BE: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009, 15: 7502–7509. 10.1158/1078-0432.CCR-09-0189
Engelman JA, Zejnullahu K, Mitsudomi T, et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316: 1039–1042. 10.1126/science.1141478
Yun CH, Mengwasser KE, Toms AV, et al.: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105: 2070–2075. 10.1073/pnas.0709662105
Su KY, Chen HY, Li KC, et al.: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012, 30: 433–440. 10.1200/JCO.2011.38.3224
Miller VA, Hirsh V, Cadranel J, et al.: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13: 528–538. 10.1016/S1470-2045(12)70087-6
Yang J CH, Schuler MH, Yamamoto N, et al.: LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Abstract, ASCO 2012.
Nakagawa T, Takeuchi S, Yamada T, et al.: Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 2012, 11: 2149–2157. 10.1158/1535-7163.MCT-12-0195
Ohashi K, Sequist LV, Arcila ME, et al.: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 2012, 109: E2127-E2133. 10.1073/pnas.1203530109
Yamamoto C, Basaki Y, Kawahara A, et al.: Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010, 70: 8715–8725. 10.1158/0008-5472.CAN-10-0043
Roberts PJ, Stinchcombe TE, Der CJ, et al.: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010, 28: 4769–4777. 10.1200/JCO.2009.27.4365
Linardou H, Dahabreh IJ, Kanaloupiti D, et al.: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-smll-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9: 962–972. 10.1016/S1470-2045(08)70206-7
Huang S, Armstrong EA, Benavente S, et al.: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004, 64: 5355–5362. 10.1158/0008-5472.CAN-04-0562
Choi EJ, Ryu YK, Kim SY, et al.: Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implications in radiation response. Mol Cancer Res 2010, 8: 1027–1036. 10.1158/1541-7786.MCR-09-0507
Nagata Y, Takahashi A, Ohnishi K, et al.: Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol 2010, 37: 1001–1010.